Clinical Trials Logo

Filter by:
NCT ID: NCT05798936 Not yet recruiting - Clinical trials for Benign Thyroid Nodule

Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare the efficacy and safety of ultrasound-guided percutaneous ethanol injection and percutaneous polidocanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.

NCT ID: NCT05799716 Not yet recruiting - Bacteremia Clinical Trials

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1. How effective IVIG is in preventing donor-derived infections 2. Does IVIG has potential immunomodulatory effect on transplanted organs

NCT ID: NCT05801055 Not yet recruiting - Gastric Disease Clinical Trials

A Study to Evaluate Endoscopic Visibility of Stomach After a Combination Drink of N-acetylcysteine and Simethicone

Start date: April 1, 2023
Phase: Phase 3
Study type: Interventional

Endoscopy is the diagnostic modality for most gastroduodenal diseases. During endoscopy mucus and foam may actually interfere with the visibility of the stomach mucosa. So the mixture of mucolytic ( N-acetyl cysteine) and anti-foaming agents ( simethicone) agents may disperse the bubbles and mucus in the stomach and enhance gastric visibility. This unique combination drink given 20-30 minutes prior to endoscopy is absolutely safe. There are previous studies from India, which was retrospective study. So, we have planned to conduct this randomized controlled trial on this issue. Adult patients undergoing diagnostic endoscopy will be randomized and one group (100 patients) will be given the combination drink whereas another group 9100 patients) will undergo an endoscopy after overnight fasting only, as a placebo drink may actually hamper the endoscopic visibility. Our primary outcome, gastric visibility will be assessed using a standard visibility scoring system.

NCT ID: NCT05801328 Not yet recruiting - Clinical trials for Maxillofacial Injuries

Comparison Between Occlusal Versus Apical Bent Wires in Patients on Erich Arch Bar

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Patients with jaw fractures requires placement of Erich arch bar for immobilization of the fractured jaw. However, the usage of Erich arch bar is associated with an increased in the incidence of mucosal trauma and plaque accumulation. Conventionally, the ends of the wires has always been placed apical to the teeth. This study aims to determine if a change in the placement of the wire by directing it to the occlusal direction will reduce the incidence of mucosal trauma, plaque accumulation and if the stability of the Erich arch bar will be affected by this intervention. The patients' teeth will be divided into left and right side and randomized into control side (wires end apically) and interventional side (wires end occlusally)

NCT ID: NCT05801718 Not yet recruiting - Clinical trials for Chronic Medical Diseases

Growth Parameters & Body Mass Index in Children With Chronic Diseases

Start date: April 1, 2023
Phase:
Study type: Observational

Deviations from the normal pattern of growth may be the first clues to pathology as in many chronic diseases evaluated clinically by anthropometric measurements & body mass index. Growth impairment in children with chronic diseases is associated with disruption of the growth hormone (GH) and predominantly results from undernutrition, chronic inflammation and prolonged corticosteroid treatment. Undernutrition leads to major adaptations in the endocrine system towards conserving energy, diverting substrates away from growth and reproduction, and providing alternative sources of energy for critical body homeostasis. chronic inflammatory processes exacerbate undernutrition through proinflammatory cytokines such as interleukin-1&6 and tumor necrosis factor. These growth-regulating mechanisms are disturbed further by corticosteroids used in some chronic conditions for their anti-inflammatory and immunosuppressive properties. Growth impairment occurs with many chronic conditions e g: Congenital heart dieases (CHD), chronic pulmonary diseases such as bronchial asthma, Gastrointestinal diseases sch as inflammatory bowel disease ,Chronic liver diseases , Chronic renal diseases, Chronic hemolytic anemia and chronic Central nervous system diseases.

NCT ID: NCT05801822 Not yet recruiting - Clinical trials for Subclinical Hypothyroidism

Screening of Subclinical Hypothyroidism in Pregnant Women

Start date: April 1, 2023
Phase:
Study type: Observational

this study may help the physicians to evaluate the practice of universal screening of sub-clinical hypothyroidism and thyroid-stimulating hormone level. Detection of sub-clinical hypothyroidism early in pregnancy through thyroid-stimulating hormone sampling in the first trimester will allow achieving proper management and better maternal and neonatal outcome of these patients.

NCT ID: NCT05802667 Not yet recruiting - Inflammation Clinical Trials

A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction

Start date: April 1, 2023
Phase:
Study type: Observational

By including patients with acute myocardial infarction, mast cell markers were analyzed and the relationship between mast cells and patients with acute myocardial infarction was analyzed

NCT ID: NCT05803161 Not yet recruiting - Clinical trials for Functional Constipation

Congrong Runtong Oral Liquid in the Treatment of Functional Constipation (Yang-deficiency Type)

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Using a placebo as a control, this study aims to preliminarily evaluate the clinical efficacy of Congrong Runtong oral liquid for the treatment of functional constipation (Yang-deficiency type), explore the optimal dosage of Congrong Runtong oral liquid for functional constipation (Yang-deficiency type) to provide a basis for dosage selection in Phase III clinical trials, and observe the safety of clinical use of Congrong Runtong oral liquid.

NCT ID: NCT05806528 Not yet recruiting - Placenta Accreta Clinical Trials

Role of Placental Invasion Index in Decision Making of Placenta Accreta

Start date: April 1, 2023
Phase:
Study type: Observational

This study will be conducted on women who have a diagnosis of placenta previ and using ultrasound to make the placenta invasion index and compare the accuracy of the diagnosis during the caesarean section whether it is accreta or not with determining the site and depth of invasion

NCT ID: NCT05806918 Not yet recruiting - Herpes Zoster Clinical Trials

Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer

Start date: April 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trail is to demonstrate the non-inferiority of recombinant human interferon α-2b gel (ZK-A03) after changing the manufacturer of the active ingredient in patients with herpes zoster. This double-blind study will enroll approximately 368 adult patients with herpes zoster in China. Eligible patients will be assigned randomly at a 1:1 ratio. For each patient who is included, treatment may last up to 10 days. During the study, subjects will be treated with recombinant human interferon α-2b gel (either before or after the alteration of the active ingredient manufacturer), at a frequency of four times a day, together with a background therapy of valaciclovir hydrochloride.